Home > News > Drug find worth $700 million
March 10th, 2008
Drug find worth $700 million
Abstract:
In a chemist's version of a winning PowerBall ticket, Richard Silverman's discovery eventually became a blockbuster drug that showered him and Northwestern University with more than $700 million in royalties.
Still, there was disappointment along the way. Once Pfizer Inc., the giant pharmaceutical concern, took control of the drug's development, Silverman was pushed aside.
"I was an outsider," said Silverman, 61. "There was no talk with their scientists. No comments. They had a launch party for the drug, and I asked to come. Nope. No party for me. They take your stuff and tell you to go away."
While it is common for university professors in places like California's Silicon Valley and Boston's Highway 128 to commercialize their research, it is less common in the Midwest, said Jon Wasserman, a Chicago-based attorney specializing in nanotechnology issues.
Source:
chicagotribune.com
Bookmark:
| Related News Press |
News and information
Decoding hydrogen‑bond network of electrolyte for cryogenic durable aqueous zinc‑ion batteries January 30th, 2026
COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers/Posters
Metasurfaces smooth light to boost magnetic sensing precision January 30th, 2026
COF scaffold membrane with gate‑lane nanostructure for efficient Li+/Mg2+ separation January 30th, 2026
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||